Alkermes News

Following Thursday and Friday's precipitous selloff in the equity market - and the last month's for that matter - I once again found inspiration to look elsewhere for investment opportunities.

CAMBRIDGE, Mass. - Alkermes, Inc. today announced the initiation of a phase 3 clinical trial of VIVITROL for the treatment of opioid dependence.

Cambridge biotech firm Alkermes Inc. has begun a Phase 3 clinical trial of its Vivitrol long-term treatment for opioid dependence, the company reports.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

The firm developed and manufactures Vivitrol, a treatment for alcohol dependence that partner Cephalon markets in the United States.

CAMBRIDGE, Massachusetts : Shares of Alkermes Inc. rose more than 6 percent in morning trading after the Cambridge, Massachusetts-based biotechnology company raised its financial expectations.

No, it's not a dance craze. Contago is a condition of supply and demand, essentially a fancy word to say that prices for items, typically commodities, are cheaper now than they would be at some point down the ...

Shares of Alkermes Inc. rose 9 percent in opening trading after the Cambridge-based biotechnology firm raised its financial expectations.

Alkermes, Inc. today announced that its Board of Directors has authorized the expansion of its common stock repurchase program by an additional $40 million following the receipt of a $40 million payment from ...

The stock fell 18% between Thursday and Monday as investors fretted about positive data from competitor Novo Nordisk and then made a 3.3% rebound yesterday as investors liked what they saw in its own ...

Amylin Pharmaceuticals, Inc. , Eli Lilly and Company , and Alkermes, Inc. today announced results from a 52-week open label clinical study that showed the durable efficacy of exenatide once weekly, a ...

Drug stocks slipped in early action Tuesday even as shares of Amylin Pharmaceuticals were on the rebound after releasing a favorable study on the effectiveness of a long-acting version of its diabetes drug ...

Zacks.com releases the latest Analyst Interview. Today ' s interview is with senior analyst Grant Zeng, who discusses Celgene , Regeneron , Myriad Genetics , Alkermes and Trimeris .

Biotechnology company Alkermes Inc. said Thursday it swung to a fiscal 2008 fourth-quarter loss on charges for cutting jobs and shuttering a facility in the wake of partner Eli Lilly & Co.'s decision to end ...

Drug stocks slid Friday afternoon as shares of Alkermes Inc. fell following a downgrade by analysts at Wm.

The brokerage cut ALKS to "neutral" from "outperform" after ALKS reported weaker-than-expected earnings for the fourth quarter.

Market News with ForexGen China's Feb. trade surplus shrinks 63 per cent; gap with U.S.A., Europe narrows BEIJING - China's politically sensitive trade surplus plunged in February as U.S. and European demand ... via The Capital Letter

Main Category: Bipolar Also Included In: Mental Health ; Psychology / Psychiatry Article Date: 16 Apr 2008 - 4:00 PDT printer friendly view / write opinions rate article Alkermes, Inc. via Medical News Today

Alkermes Inc. wants federal regulators to use its signature schizophrenia drug to also treat bipolar disorder. via Boston Business Journal

“Given the current market sentiment”

MNKD / PFE There's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather ... via The Biotech Stock Blog